论文部分内容阅读
目的探讨多药耐药相关蛋白(MRP)、P53、雌激素受体(ER)、孕激素受体(PR)蛋白在乳腺癌组织中表达的特性,相关性和临床意义。方法应用SP免疫组织化学法检测73例乳腺癌标本中MRP、P53、ER、PR蛋白的表达,结合临床、病理资料进行回顾性分析。结果 MRP、P53、ER、PR在乳腺癌中的阳性表达率依次为35.6%(26/73)、69.9%(51/73)、60.3%(44/73)和56.2%(41/73),表达与患者年龄、肿瘤大小、腋窝淋巴结转移和组织学分级无显著相关性,MRP与P53之间存在显著正相关性(P<0.05),MPR与ER/PR的表达无显著性相关(P>0.05),而P53与ER/PR的表达显著相关(P<0.05)。结论乳腺癌MRP、P53、ER和PR的表达为乳腺癌的药物治疗提供了客观参考指标,对制定个体化方案和预后有一定帮助。
Objective To investigate the characteristics, relativity and clinical significance of multidrug resistance-related protein (MRP), P53, estrogen receptor (ER) and progesterone receptor (PR) protein in breast cancer. Methods SP immunohistochemistry was used to detect the expression of MRP, P53, ER and PR in 73 cases of breast cancer. The clinical and pathological data were retrospectively analyzed. Results The positive rates of MRP, P53, ER and PR in breast cancer were 35.6% (26/73), 69.9% (51/73), 60.3% (44/73) and 56.2% (41/73), respectively There was no significant correlation between the expression of MRP and P53 (P <0.05), but there was no significant correlation between MPR and ER / PR (P> 0.05), while the expression of P53 and ER / PR were significantly correlated (P <0.05). Conclusion The expression of MRP, P53, ER and PR in breast cancer provides an objective reference for the treatment of breast cancer, which is helpful to develop individualized plans and prognosis.